source
- Definium Therapeutics reports positive Phase 3 results for oral LSD anxiety drug DT120Definium Therapeutics announced Monday that its experimental oral LSD formulation, DT120, achieved positive outcomes in a Phase 3 trial targeting an anxiety disorder. The trial, the company's thir…
- Akeso and Summit report survival advantage for PD-1xVEGF combo over KeytrudaAt the American Society of Clinical Oncology (ASCO) 2026 meeting, Akeso Biopharma and its partner Summit Therapeutics announced new survival results for their experimental PD‑1×VEGF bispecific anti…